Glomerulopatia por IgA com crescentes fibrocelulares e associada à psoríase
nefropatia psoriásica?
DOI:
https://doi.org/10.23925/1984-4840.2021v23i3/4a9Palabras clave:
glomerulonefrite por IgA, psoríase, artrite psoriásica, adalimumab, inibidores do fator de necrose tumoralResumen
Alguns estudos têm demonstrado uma ligação entre glomerulonefrite por IgA e psoríase e/ou uso de drogas anti-TNF. Descrevemos o caso de um paciente com artrite psoriática, em uso de anti-TNF por quatro anos, que apresentou nefropatia por IgA agravada por crescentes na biópsia renal e insuficiência renal necessitando de hemodiálise. Após a realização de terapia com metilprednisolona IV e três meses de corticoide oral, houve melhora significativa na função renal e proteinúria. O tratamento de diálise foi interrompido e tratamentos com SGLT-2 inibidores foram iniciados.
Descargas
Métricas
Citas
Lai KN, Leung JCK, Tang SCW. Recent advances in the understanding and management of IgA nephropathy. F1000Res. 2016;5:F1000 Faculty Rev-161. doi: 10.12688/f1000research.7352.1. eCollection 2016.
Floege J, Rauen T, Tang SCW. Current treatment of IgA nephropathy. Semin Immunopathol. 2021;43(5):717-28. doi: 10.1007/s00281-021-00888-3.
Novak J, Barratt J, Julian BA, Renfrow MB. Aberrant gycosylation of the IgA1 molecule in IgA nephropathy. Semin Nephrol. 2018;38(5):461-476. doi: 10.1016/j.semnephrol.2018.05.016.
Wyatt RJ, Julian BA. IgA Nephropathy. N Engl J Med. 2013;368(25):2402-14. doi: 10.1056/NEJMra1206793.
Lv J, Yang Y, Zhang H, Chen W, Pan X, Guo Z, et al. Prediction of outcomes in crescentic IgA nephropathy in a multicenter cohort study. J Am Soc Nephrol. 2013;24(12):2118-25. doi: 10.1681/ASN.2012101017.
Garces CC, Hernandez Garcilazo N, Sharma A, Nader G. Severe psoriasis presenting with rapidly progressive (crescentic) IgA-predominant glomerulonephritis. BMJ Case Rep. 2021;14(5):e242627. doi: 10.1136/bcr-2021-242627.
Rovin BH, Adler SG, Barratt J, Bridoux F, Burdge KA, Chan TM, et al. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021;100(4S):S1-S276. doi: 10.1016/j.kint.2021.05.021.
Barbour SJ, Coppo R, Zhang H, Liu Z-H, Suzuki Y, Matsuzaki K, et al. Evaluating a new international risk-prediction tool in IgA nephropathy. JAMA Intern Med. 2019;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600.
Saha MK, Julian BA, Novak J, Rizk DV. Secondary IgA nephropathy. Kidney Int. 2018;94(4):674-681. doi: 10.1016/j.kint.2018.02.030. Epub 2018 May 24.
Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361(5):496-509. doi: 10.1056/NEJMra0804595.
Kamiya K, Kishimoto M, Sugai J, Komine M, Ohtsuki M. Risk factors for the development of psoriasis. Int J Mol Sci. 2019;20(18):4347. doi: 10.3390/ijms20184347.
Rendon A, Schäkel K. Psoriasis pathogenesis and treatment. Int J Mol Sci. 2019;20(6):1475. doi: 10.3390/ijms20061475.
Boehncke W-H, Schön MP. Psoriasis. Lancet. 2015;386(9997):983-94. doi: 10.1016/S0140-6736(14)61909-7.
Guilhou J-J, Clot J, Meynadier J, Lapinski H. Immunological aspects of psoriasis. J Invest Dermatol. 1982;78(4):313-5. doi: 10.1111/1523-1747.ep12507392.
Ahuja TS, Funtanilla M, de Groot JJ, Velasco A, Badalamenti J, Wilson S. IgA nephropathy in psoriasis. Am J Nephrol. 1998;18(5):425-9. doi: 10.1159/000013388.
Grandinetti V, Baraldi O, Comai G, Corradetti V, Aiello V, Bini C, et al. Renal dysfunction in psoriatic patients. G Ital Nefrol. 2020;37(1):2020-vol1.
Dervisoglu E, Akturk AS, Yildiz K, Kiran R, Yilmaz A. The spectrum of renal abnormalities in patients with psoriasis. Int Urol Nephrol. 2012;44(2):509-14. doi: 10.1007/s11255-011-9966-1. Epub 2011 Apr 20.
Bounia CA, Theodoropoulou EN, Liossis S-NC. Glomerulonephritis in two patients with SpA treated with TNF-α blockers and a review of the literature. Biologics. 2021;15:61-6. doi: 10.2147/BTT.S297712. eCollection 2021.
Stokes MB, Foster K, Markowitz GS, Ebrahimi F, Hines W, Kaufman D, et al. Development of glomerulonephritis during anti-TNF-α therapy for rheumatoid arthritis. Nephrol Dial Transplant. 2005;20(7):1400-6. doi: 10.1093/ndt/gfh832. Epub 2005 Apr 19.
Krug B, Gonçalves C, Neves C, Barone C, Oliveira Junior H, Leite L. Protocolo Clínico e Diretrizes Terapêuticas da Psoríase. Brasília (DF): Ministério da Saúde; 2020. 79 p.
Hugh JM, Weinberg JM. Update on the pathophysiology of psoriasis. Cutis. 2018;102(5S):6-12.
Dattilo G, Borgia F, Guarneri C, Casale M, Bitto R, Morabito C, et al. Cardiovascular risk in psoriasis: current state of the art. Curr Vasc Pharmacol. 2019;17(1):85-91. doi: 10.2174/1570161115666171116163816.
Manolis AA, Manolis TA, Melita H, Manolis AS. Psoriasis and cardiovascular disease: the elusive link. Int Rev Immunol. 2019;38(1):33-54. doi: 10.1080/08830185.2018.1539084. Epub 2018 Nov 20.
Grewal SK, Wan J, Denburg MR, Shin DB, Takeshita J, Gelfand JM. The risk of IgA nephropathy and glomerular disease in patients with psoriasis: a population-based cohort study. Br J Dermatol. 2017;176(5):1366-1369. doi: 10.1111/bjd.14961. Epub 2017 Mar 5.
Ungprasert P, Raksasuk S. Psoriasis and risk of incident chronic kidney disease and end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol. 2018;50(7):1277-1283. doi: 10.1007/s11255-018-1868-z. Epub 2018 Apr 11.
Visconti L, Leonardi G, Buemi M, Santoro D, Cernaro V, Ricciardi CA, et al. Kidney disease and psoriasis: novel evidences beyond old concepts. Clin Rheumatol. 2016;35(2):297-302. doi: 10.1007/s10067-015-3126-4. Epub 2015 Nov 28.
Conti A, Giovannini L, Mandel VD, Odorici G, Lasagni C, Bigi L, et al. Chronic kidney disease in psoriasis: a cohort study. J Dtsch Dermatol Ges. 2020;18(5):438-445. doi: 10.1111/ddg.14087. Epub 2020 Apr 20.
Cecchi R, Seghieri G, Gironi A, Tuci F, Giomi A. Relation between urinary albumin excretion and skin involvement in patients with psoriasis. Dermatology. 1992;185(2):93-5. doi: 10.1159/000247420.
Masson W, Lobo M, Molinero G. Psoriasis and cardiovascular risk: a comprehensive review. Adv Ther. 2020;37(5):2017-33. doi: 10.1007/s12325-020-01346-6. Epub 2020 Apr 20.
Boehncke W-H. Systemic inflammation and cardiovascular comorbidity in psoriasis patients: causes and consequences. Front Immunol. 2018;9:579. doi: 10.3389/fimmu.2018.00579. eCollection 2018.
Vaz AS, Penteado R, Cordinhã C, Carmo C, Gomes C. IgA vasculitis (Henoch-Schönlein purpura) nephritis and psoriasis in a child: is there a relationship? J Bras Nefrol. 2021;43(4):603-607. doi: 10.1590/2175-8239-JBN-2020-0101.
Bantis C, Stangou M, Schlaugat C, Alexopoulos E, Pantzaki A, Memmos D, et al. Is Presence of ANCA in crescentic IgA nephropathy a coincidence or novel clinical entity? A case series. Am J Kidney Dis. 2010;55(2):259-68. doi: 10.1053/j.ajkd.2009.09.031. Epub 2009 Dec 30.
Bhagat Singh AK, Jeyaruban AS, Wilson GJ, Ranganathan D. Adalimumab-induced IgA nephropathy. BMJ Case Rep. 2019;12(3):e226442. doi: 10.1136/bcr-2018-226442.
Wei SS, Sinniah R. Adalimumab therapy exacerbates IgA glomerulonephritis acute renal injury and induces lupus autoantibodies in a psoriasis patient. Case Rep Nephrol. 2013;2013:812781. doi: 10.1155/2013/812781. Epub 2013 Jul 24.
Mertelj T, Smrekar N, Kojc N, Lindič J, Kovač D. IgA Nephropathy in a patient treated with adalimumab. Case Rep Nephrol Dial. 2021;11(2):233-240. doi: 10.1159/000515585. eCollection 2021 May-Aug.
Descargas
Publicado
Cómo citar
Número
Sección
Licencia
Derechos de autor 2023 Revista da Faculdade de Ciências Médicas de Sorocaba
Esta obra está bajo una licencia internacional Creative Commons Atribución-NoComercial 4.0.
Os autores no momento da submissão transferem os direitos autorais, assim, os manuscritos publicados passam a ser propriedade da revista.
O conteúdo do periódico está licenciado sob uma Licença Creative Commons 4.0, esta licença permite o livre acesso imediato ao trabalho e que qualquer usuário leia, baixe, copie, distribua, imprima, pesquise ou vincule aos textos completos dos artigos, rastreando-os para indexação, passá-los como dados para o software, ou usá-los para qualquer outra finalidade legal.
Este obra está licenciada com uma Licença 